Tilray surged Wednesday alongside Canopy Growth and Aurora Cannabis, but one number from 2026 tells a very different story about why today's rally leaves the real problem untouched.
One ETF promises to hand cautious investors a clean shot at the U.S. cannabis trade without the chaos of OTC accounts and illiquid tickers, but the plumbing inside this fund is far…
Trey Thoelcke Cannabis investors have watched rescheduling euphoria ignite and incinerate capital at least four times since 2018, and a fresh DEA hearing is now on the calendar. The question is whether this cycle…
Federal cannabis policy moved from theory to action this spring, and three ETFs sit closest to the trade. The AdvisorShares Pure US Cannabis ETF (NYSEARCA:MSOS), the Amplify Seymour Cannabis ETF (NYSEARCA:CNBS), and…
Cannabis ETFs entered 2026 after multiple fund closures, stalled federal reform, and a prolonged multi‑year drawdown in underlying equities. The contraction of the product lineup has left a smaller group of actively…
Retail investors in r/options are making an unusual bet on AdvisorShares Pure US Cannabis ETF (NYSEARCA:MSOS), and the activity is hard to ignore. The post reflects the speculative tone common in options-focused…
The cannabis sector is one which many may have rightly described as a bubble seven or eight years ago. That’s because it was. Valuations in this sector got to obscene levels, with…
The AdvisorShares Pure US Cannabis ETF has spent the last month on a rollercoaster. After climbing to $6.45 in mid-December 2025, shares dropped 26% to around $4.80 by mid-January. The decline came…
Amplify Seymour Cannabis ETF (NYSEARCA:CNBS) posted a 17% gain in 2025, but that masks the real story. The fund surged 37% in December alone after President Trump signed an executive order directing…
